Mirum Pharmaceuticals To Showcase Data From Its LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting November 15-19, 2024
Mirum Pharmaceuticals To Showcase Data From Its LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting November 15-19, 2024
- Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis
- 迟发报告将展示VANTAGE研究评估volixibat在原发性胆汁性胆管炎中的数据
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will present data at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting, taking place November 15-19, 2024, in San Diego, California.
Mirum Pharmaceuticals, Inc.（纳斯达克：MIRM）今天宣布，将在美国肝病研究协会（AASLD）举行的肝脏会议上发布数据，该会议将于2024年11月15日至19日在加利福尼亚州圣地亚哥举行。
Enclosed below are the titles that have been accepted for presentation during the meeting. The abstracts are available via the AASLD website. Full analyses will be available following their presentation within the Publications & Presentation section on Mirum's website.
以下是会议期间接受报告的标题。摘要可通过AASLD网站获取。完整分析将在Mirum网站的出版物与报告部分的展示后提供。
